Udhayvir Grewal (@UGrewalMD) ranks #18 among US gi cancer KOLs on X in 2026, by engagement from fellow physicians. 19 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: ACTICCA-1, RASolute 302. CMS Open Payments lists $106 in 2025 general payments.
At a Glance
- 2 posts naming a trial in 2026
- 2 trials discussed by name
- GI Cancer: US #18 · 19 physicians engaged
- CMS Open Payments lists $106 in 2025 general payments.
This Month
What Udhayvir Grewal has posted in the last 30 days. Updated November 10, 2026.
This is quite disappointing. ACTICCA-1 tells us that we need to move beyond chemo. >50% patients experience recurrence by 2 years or so, no matter what regimen of chemo you deploy in the adjuvant setting. We need novel therapies in the adjuvant space. Will ARTEMIDE-Biliary 01 be it?
Who Amplifies Udhayvir Grewal
Physicians who reposted Udhayvir Grewal’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GI Cancer | #18 | — | 19 | 20 | Full ranking |
What Colleagues Are Saying About Udhayvir Grewal
2026 posts by fellow physicians that mention @UGrewalMD, quoted word for word.
Hopefully coming soon to a GI clinic near you; Telisotuzumab has very compelling data in refractory CRC. Looking forward to the confirmatory studies. Was a great experience writing this editorial for @JCO_ASCO with @TimothyJBrownMD @UGrewalMD and @MuhammetOzerMD. #ASCO26 https://t.co/SVutUxT74s
Trials Udhayvir Grewal Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| ACTICCA-1 | 1 | #6 of 8 | Oct 25, 2026 |
| RASolute 302 | 1 | #14 of 73 | Sep 3, 2026 |
Udhayvir Grewal on ACTICCA-1
This is quite disappointing. ACTICCA-1 tells us that we need to move beyond chemo. >50% patients experience recurrence by 2 years or so, no matter what regimen of chemo you deploy in the adjuvant setting. We need novel therapies in the adjuvant space. Will ARTEMIDE-Biliary 01 be it?
Udhayvir Grewal on RASolute 302
All of the negative comments about daraxonrasib center around how it’s not a “cure” for pancreatic cancer. For the longest time, we’ve dealt with a substandard therapy-chemotherapy; and watched our patients succumb to this awful disease. On RASolute302- not only did patients live longer and tolerate the therapy better than 2L chemo- they were also more likely to receive subsequent line therapy. That is indeed something to celebrate. Most importantly- this isn’t THE cure we’ve been looking for but this is certainly the dawn of a new era that we’ve all been anticipating for so long. Every therapy has AEs and will need fine tuning and real world experience before it becomes more tolerable for the not-so-fit patients in clinic. Drug pricing is also not an issue unique to this drug-it is a systemic issue that needs addressing on multiple levels. It’s so easy to be an “expert critic” for likes and engagement on social media and so hard to work towards moving the needle forward for patients.
Udhayvir Grewal’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Phase 1b/2 ZL-1310 (DLL3 ADC) in pretreated NECs presented by @rohit_thum at #AACR26 : ORR 38.2% (13/34), responses across multiple primaries.TEAEs in 97.8%, G3+ ~30% (mostly GI/heme). DLL3 H-score not clearly predictive!! Encouraging results especially with some durable responses. That no responses were observed in those with prior irinotecan exposure makes sense due to the topoisomerase I inh PL. Glad to see that the DLL3 space is rapidly expanding and will likely evolve to allow effective sequencing of multiple DLL3-targeting therapies. ? BiTE followed by ADC? @NANETS1 @NCFCancer @lisayentwin
Not enough people are screaming with excitement about how insanely good these numbers are! 82% ORR, with 100% 9 month PFS in 2 L MTAP del PDAC with ongoing responses at 12 months. Pure insanity! #precisionmedicine 🤌 https://t.co/x2Hnp6ZSh2
Phase 1/2 data for Daraxonrasib are now published in @NEJM - Patients with pretreated PDAC harboring KRAS, NRAS, or HRAS mutations at codons 12, 13, or 61- received Daraxonrasib once daily in 21-day cycles at doses ranging from 10 mg to 400 mg. MTD was not reached, 400 mg was maximum administered dose. 🚨📛Important to highlight the toxicities here (300 mg, n=83)- rash (in 90%), stomatitis or mucositis (in 54%), diarrhea (in 52%), and nausea (in 39%)--Grade 3 or higher occurred in 34% of the patients. Dose modifications:48% (dose interruption: 43% and dose reduction: 30%). However, no patients discontinued treatment due to AEs. 📈📊Now looking at efficacy- at a median follow-up of 17 months, mPFS=8.5 months, mOS=13.1 months. ORR 29% with median time until objective response= 2.6 months and duration of response= 8.2 months. 👏🔥 💯💯Overall impressive data for efficacy but it is obvious that this comes at a price, i.e., toxicity! But this is true for any drug, especially TKIs- rash, GI tox, etc are not new toxicities with TKIs. I bet as our experience with these agents grows, we will find ways to minimize these and preserve QoL as our patients continue to benefit from these game changing novel agents. This sets the stage for whats coming at #ASCO26 https://t.co/asqUOhvq1H
Watch me and my buddies @GIMedOnc and @TimothyJBrownMD discuss what all we’re looking forward to the most in GI oncology abstracts at #ESMO26 @TheGutOncLab https://t.co/4dt7M5xc4q
https://t.co/rfvV430HGK
Industry Payments
CMS Open Payments · 2025 general payments
$106 across 4 payments